GC1118

GC1118 (GC-1118A) is a fully human anti-EGFR monoclonal antibody with binding affinity of 0.16 nM (KD) to EGFR. GC1118 displays potent inhibitory effects on high- and low-affinity EGFR ligand-induced signaling. GC1118 shows potent anti proliferative activity in KRAS wild-type and KRAS mutant cells. GC1118 can reach the tumor by crossing both BBB (blood-brain barrier) and BTB (brain-tumor barrier) and shows superior anti-tumor effects in various mice xenograft models. GC1118 can be used for the researches of cancer, such as colorectal cancer[1][2][3][4].

GC-1118A

12352203

Akt; EGFR; PERK

Cell Cycle/DNA Damage; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Cancer-Kinase/protease

Cancer

[1]ark JE, et al. GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer. Gastric Cancer. 2019 Sep;22 (5) :932-940. |[2]Lee K, et al. Therapeutic Efficacy of GC1118, a Novel Anti-EGFR Antibody, against Glioblastoma with High EGFR Amplification in Patient-Derived Xenografts. Cancers (Basel) . 2020 Oct 31;12 (11) :3210.|[3]Lim Y, et al. GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands. Mol Cancer Ther. 2016 Feb;15 (2) :251-63.|[4]Lee HW, et al. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts. Int J Mol Sci. 2019 Nov 24;20 (23) :5894.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991571/

Inhibitory Antibodies

No Development Reported